Completed NA INTERVENTIONAL 1-arm NCT02900092

Augmentation of Treatment-Resistant Depression With An Analog of the Neuroactive Steroid Allopregnanolone

Treatment-Resistant Depression Augmentation Therapy With An Analog of the Neuroactive Steroid Allopregnanolone: A Pilot Study

Sponsor: Massachusetts General Hospital

Conditions Major Depressive Disorder

Interventions Ganaxolone

Updated 9 times since 2017 Last updated: Feb 13, 2019 Started: Nov 30, 2016 Primary completion: Jan 12, 2018 Completion: Jan 12, 2018

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Major Depressive Disorder, this trial is completed. The trial is conducted by Massachusetts General Hospital and has accumulated 9 data snapshots since 2016. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed NA
Jul 2024 — Sep 2024 [monthly]

Completed NA
Jan 2021 — Jul 2024 [monthly]

Completed NA
Mar 2019 — Jan 2021 [monthly]

Completed NA
Oct 2018 — Mar 2019 [monthly]

Completed NA

Status: Recruiting → Completed

▶ Show 4 earlier versions

Jun 2018 — Oct 2018 [monthly]

Recruiting NA
Nov 2017 — Jun 2018 [monthly]

Recruiting NA
Feb 2017 — Nov 2017 [monthly]

Recruiting NA
Jan 2017 — Feb 2017 [monthly]

Recruiting NA

First recorded

Nov 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Massachusetts General Hospital

Data source: Massachusetts General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Boston, United States